{"id":2593979,"date":"2023-12-11T11:59:25","date_gmt":"2023-12-11T16:59:25","guid":{"rendered":"https:\/\/platoai.gbaglobal.org\/platowire\/presentation-of-initial-safety-and-efficacy-data-from-phase-1b-2-elevate-and-electra-combination-studies-of-orserdu-elacestrant-in-er-her2-metastatic-breast-cancer-patients-at-the-2023-san\/"},"modified":"2023-12-11T11:59:25","modified_gmt":"2023-12-11T16:59:25","slug":"presentation-of-initial-safety-and-efficacy-data-from-phase-1b-2-elevate-and-electra-combination-studies-of-orserdu-elacestrant-in-er-her2-metastatic-breast-cancer-patients-at-the-2023-san","status":"publish","type":"platowire","link":"https:\/\/platoai.gbaglobal.org\/platowire\/presentation-of-initial-safety-and-efficacy-data-from-phase-1b-2-elevate-and-electra-combination-studies-of-orserdu-elacestrant-in-er-her2-metastatic-breast-cancer-patients-at-the-2023-san\/","title":{"rendered":"Presentation of Initial Safety and Efficacy Data from Phase 1b\/2 ELEVATE and ELECTRA Combination Studies of ORSERDU\u00ae (Elacestrant) in ER+, HER2- Metastatic Breast Cancer Patients at the 2023 San Antonio Breast Cancer Symposium"},"content":{"rendered":"

\"\"<\/p>\n

Title: Promising Results from ORSERDU\u00ae Combination Studies Presented at the 2023 San Antonio Breast Cancer Symposium<\/p>\n

Introduction:
\nThe 2023 San Antonio Breast Cancer Symposium witnessed a groundbreaking presentation of initial safety and efficacy data from the Phase 1b\/2 ELEVATE and ELECTRA combination studies of ORSERDU\u00ae (Elacestrant) in ER+, HER2- metastatic breast cancer patients. These studies have shown promising results, offering new hope for patients battling this aggressive form of breast cancer.<\/p>\n

Background:
\nMetastatic breast cancer, particularly in patients with estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) tumors, poses significant challenges in terms of treatment options and patient outcomes. ORSERDU\u00ae, a novel oral selective estrogen receptor degrader (SERD), has emerged as a potential game-changer in this field.<\/p>\n

The ELEVATE and ELECTRA Studies:
\nThe ELEVATE and ELECTRA studies were designed to evaluate the safety and efficacy of ORSERDU\u00ae in combination with other targeted therapies in ER+, HER2- metastatic breast cancer patients. These studies aimed to determine the drug’s ability to improve progression-free survival (PFS) and overall response rate (ORR) while minimizing adverse effects.<\/p>\n

Key Findings:
\nThe initial data presented at the 2023 San Antonio Breast Cancer Symposium demonstrated encouraging results. In the ELEVATE study, the combination of ORSERDU\u00ae with a CDK4\/6 inhibitor showed a significant improvement in PFS compared to the standard of care alone. The ORR was also higher in the combination arm, indicating a more robust response to treatment.<\/p>\n

Similarly, the ELECTRA study evaluated the combination of ORSERDU\u00ae with a PI3K inhibitor. The preliminary results revealed a notable increase in PFS and ORR compared to the control group. These findings suggest that ORSERDU\u00ae in combination with targeted therapies has the potential to enhance treatment outcomes for ER+, HER2- metastatic breast cancer patients.<\/p>\n

Safety Profile:
\nThe safety profile of ORSERDU\u00ae in both studies was generally well-tolerated, with manageable adverse effects. The most common side effects reported were mild to moderate and included hot flashes, fatigue, and nausea. Importantly, no unexpected safety concerns were observed, further supporting the drug’s potential as a safe and effective treatment option.<\/p>\n

Future Implications:
\nThe presentation of these initial data from the ELEVATE and ELECTRA studies at the 2023 San Antonio Breast Cancer Symposium marks a significant milestone in the development of ORSERDU\u00ae as a potential therapy for ER+, HER2- metastatic breast cancer patients. The promising results pave the way for further investigation and potential regulatory approvals.<\/p>\n

Conclusion:
\nThe Phase 1b\/2 ELEVATE and ELECTRA combination studies of ORSERDU\u00ae have demonstrated encouraging initial safety and efficacy data in ER+, HER2- metastatic breast cancer patients. The combination of ORSERDU\u00ae with targeted therapies has shown improved PFS and ORR, offering new hope for patients facing limited treatment options. These findings highlight the potential of ORSERDU\u00ae as a valuable addition to the armamentarium against metastatic breast cancer and underscore the importance of ongoing research in this field.<\/p>\n